阿杜卡奴单抗治疗阿尔茨海默病中被忽视的代表性不足人群：伦理评论
Under-Represented Populations Left Out of Alzheimer's Disease Treatment with Aducanumab: Commentary on Ethics.
作者信息
Padala Sanjana P, Yarns Brandon C
机构信息
Vanderbilt University, College of Arts and Sciences/Medicine, Health and Society, Nashville, TN, USA.
Department of Psychiatry/Mental Health, VA Greater Los Angeles Healthcare System, Los Angeles, CA, USA.
出版信息
J Alzheimers Dis Rep. 2022 Jun 22;6(1):345-348. doi: 10.3233/ADR-220023. eCollection 2022.
Abstract
Despite controversy about the efficacy and safety of aducanumab, the FDA's fast-tracking of this medicine is truly historic. However, structural problems leading to socioeconomic disparities and systemic racism in science, healthcare, and society have left out under-represented populations. This perspective outlines the racial and socioeconomic health disparities in aducanumab treatment: 1) Disparities in the risk of Alzheimer's disease (AD), 2) Limited participation from under-represented groups in AD trials raising concerns about the generalizability of the results, 3) Questionable applicability of the amyloid hypothesis in groups under-represented in AD research, and 4) Aducanumab's initial sticker price that unfairly singled out those with lower socioeconomic backgrounds. Potential solutions are discussed.
摘要
尽管对于阿杜卡单抗的疗效和安全性存在争议，但美国食品药品监督管理局（FDA）对这种药物的快速审批确实具有历史意义。然而，科学、医疗保健和社会中导致社会经济差距和系统性种族主义的结构性问题使得代表性不足的人群被排除在外。这一观点概述了阿杜卡单抗治疗中存在的种族和社会经济健康差距：1）阿尔茨海默病（AD）风险的差异；2）代表性不足的群体在AD试验中的参与有限，这引发了对结果普遍性的担忧；3）淀粉样蛋白假说在AD研究中代表性不足的群体中的适用性存疑；4）阿杜卡单抗的初始标价不公平地针对了社会经济背景较低的人群。文中还讨论了潜在的解决方案。
相似文献
1
Under-Represented Populations Left Out of Alzheimer's Disease Treatment with Aducanumab: Commentary on Ethics.阿杜卡奴单抗治疗阿尔茨海默病中被忽视的代表性不足人群：伦理评论
J Alzheimers Dis Rep. 2022 Jun 22;6(1):345-348. doi: 10.3233/ADR-220023. eCollection 2022.
2
A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease.与最近批准用于治疗阿尔茨海默病的药物相关的科学伦理问题综述。
Sci Eng Ethics. 2023 Jan 10;29(1):2. doi: 10.1007/s11948-022-00422-0.
3
Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.阿杜卡奴单抗在阿尔茨海默病治疗中的作用：挑战与机遇。
Clin Interv Aging. 2022 May 18;17:797-810. doi: 10.2147/CIA.S325026. eCollection 2022.
4
An insider's perspective on FDA approval of aducanumab.关于阿杜卡努单抗获得美国食品药品监督管理局批准的业内人士观点。
Alzheimers Dement (N Y). 2023 May 18;9(2):e12382. doi: 10.1002/trc2.12382. eCollection 2023 Apr-Jun.
5
Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.关于美国食品药品监督管理局批准阿杜卡单抗的公众意见及潜在政策回应：一项全国代表性调查。
J Am Geriatr Soc. 2022 Jun;70(6):1685-1694. doi: 10.1111/jgs.17692. Epub 2022 Feb 7.
6
Is Aducanumab for LMICs? Promises and Challenges.阿杜卡努单抗适用于低收入和中等收入国家吗？机遇与挑战。
Brain Sci. 2021 Nov 22;11(11):1547. doi: 10.3390/brainsci11111547.
7
Aducanumab as a Novel Treatment for Alzheimer's Disease: A Decade of Hope, Controversies, and the Future.阿杜卡单抗作为阿尔茨海默病的新型治疗方法：十年的希望、争议与未来。
Cureus. 2021 Aug 31;13(8):e17591. doi: 10.7759/cureus.17591. eCollection 2021 Aug.
8
Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab.传统疗法与新疗法：比较乙酰胆碱酯酶抑制剂和N-甲基-D-天冬氨酸受体拮抗剂与阿杜卡单抗的效果
Cureus. 2022 Nov 3;14(11):e31065. doi: 10.7759/cureus.31065. eCollection 2022 Nov.
9
From monomer to fibril: Abeta-amyloid binding to Aducanumab antibody studied by molecular dynamics simulation.从单体到原纤维：通过分子动力学模拟研究 Aβ-淀粉样蛋白与 Aducanumab 抗体的结合。
Proteins. 2020 Dec;88(12):1592-1606. doi: 10.1002/prot.25978. Epub 2020 Aug 3.
10
Aducanumab for Alzheimer's disease: A regulatory perspective.阿杜卡奴单抗治疗阿尔茨海默病：监管视角。
Pharmacol Res. 2021 Sep;171:105754. doi: 10.1016/j.phrs.2021.105754. Epub 2021 Jul 2.
引用本文的文献
1
A real-world safety surveillance study of aducanumab through the FDA adverse event reporting system.一项通过美国食品药品监督管理局不良事件报告系统对阿杜卡努单抗进行的真实世界安全性监测研究。
Front Pharmacol. 2025 Mar 13;16:1522058. doi: 10.3389/fphar.2025.1522058. eCollection 2025.
2
Achieving Inclusion in Pharmacological Clinical Trials for Alzheimer's Disease.实现阿尔茨海默病药理学临床试验的包容性。
Curr Top Behav Neurosci. 2025;69:229-242. doi: 10.1007/7854_2024_522.
3
Perceptions about dementia clinical trials among underrepresented populations: a nationally representative survey of U.S. dementia caregivers.代表性不足人群对痴呆症临床试验的看法：一项针对美国痴呆症照顾者的全国代表性调查。
Alzheimers Res Ther. 2024 Oct 15;16(1):224. doi: 10.1186/s13195-024-01579-5.
4
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease.血浆 P-tau217 在早期阿尔茨海默病记忆门诊患者中评估降淀粉样蛋白免疫治疗适应证的临床应用。
Alzheimers Res Ther. 2024 Jul 6;16(1):154. doi: 10.1186/s13195-024-01521-9.
5
Perceptions about dementia clinical trials among underrepresented populations: A nationally representative survey of U.S. dementia caregivers.未充分代表人群对痴呆症临床试验的看法：一项对美国痴呆症护理人员的全国代表性调查。
Res Sq. 2024 Jun 14:rs.3.rs-4492550. doi: 10.21203/rs.3.rs-4492550/v1.
6
A service-oriented approach to clinical trial recruitment for dementia and brain health: Methods and case examples of MyAlliance for Brain Health.一种面向痴呆症和脑健康临床试验招募的服务型方法：脑健康联盟（MyAlliance for Brain Health）的方法及案例
Alzheimers Dement (N Y). 2024 Jun 20;10(2):e12475. doi: 10.1002/trc2.12475. eCollection 2024 Apr-Jun.
7
Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease.血浆P-tau217在记忆门诊早期阿尔茨海默病患者中评估淀粉样蛋白降低免疫治疗适用性的临床应用
Res Sq. 2024 May 29:rs.3.rs-3755419. doi: 10.21203/rs.3.rs-3755419/v1.
8
Evaluation and Characterization of Modified K114 Method to Localize Plaques in Rodent and Plaques and Tangles in Human Brain Tissue.改良K114方法在啮齿动物中定位斑块以及在人类脑组织中定位斑块和缠结的评估与表征
Curr Alzheimer Res. 2024;21(1):69-80. doi: 10.2174/0115672050295561240327055835.
9
Top Alzheimer's disease risk allele frequencies differ in HABS-HD Mexican- versus Non-Hispanic White Americans.阿尔茨海默病最高风险等位基因频率在西班牙裔美国人和非西班牙裔美国白人之间存在差异。
Alzheimers Dement (Amst). 2023 Dec 27;15(4):e12518. doi: 10.1002/dad2.12518. eCollection 2023 Oct-Dec.
10
Communicating and Using Dementia Risk Evidence.沟通和使用痴呆风险证据。
J Alzheimers Dis. 2022;90(3):933-944. doi: 10.3233/JAD-220722.
本文引用的文献
1
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.阿杜卡努单抗在降低淀粉样蛋白的同时产生了具有临床意义的益处。
Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.
2
ENGAGE and EMERGE: Truth and consequences?参与和浮现：真相与后果？
Alzheimers Dement. 2021 Apr;17(4):692-695. doi: 10.1002/alz.12286. Epub 2021 Mar 3.
3
Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.多民族社区研究中的血浆 p-tau181、p-tau217 和其他基于血液的阿尔茨海默病生物标志物。
Alzheimers Dement. 2021 Aug;17(8):1353-1364. doi: 10.1002/alz.12301. Epub 2021 Feb 13.
4
Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.未能证明 aducanumab 的疗效：Biogen 报告的 EMERGE 和 ENGAGE 试验分析，2019 年 12 月。
Alzheimers Dement. 2021 Apr;17(4):696-701. doi: 10.1002/alz.12213. Epub 2020 Nov 1.
5
Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.与临床正常老年人淀粉样蛋白负担增加相关的因素。
JAMA Neurol. 2020 Jun 1;77(6):735-745. doi: 10.1001/jamaneurol.2020.0387.
6
A systematic review of barriers and facilitators to minority research participation among African Americans, Latinos, Asian Americans, and Pacific Islanders.一项关于非裔美国人、拉丁裔、亚裔美国人和太平洋岛民参与少数族裔研究的障碍和促进因素的系统评价。
Am J Public Health. 2014 Feb;104(2):e16-31. doi: 10.2105/AJPH.2013.301706. Epub 2013 Dec 12.
7
Community leaders' perspectives on engaging African Americans in biobanks and other human genetics initiatives.社区领袖对让非裔美国人参与生物样本库及其他人类遗传学倡议的看法。
J Community Genet. 2013 Oct;4(4):483-94. doi: 10.1007/s12687-013-0155-z. Epub 2013 Jun 29.
8
Gender and ethnic diversity in NIMH-funded clinical trials: review of a decade of published research.美国国立精神卫生研究所资助的临床试验中的性别与种族多样性：对十年已发表研究的综述
Adm Policy Ment Health. 2007 Nov;34(6):497-503. doi: 10.1007/s10488-007-0133-z. Epub 2007 Aug 10.
9
The Tuskegee Study of Untreated Syphilis and public perceptions of biomedical research: a focus group study.塔斯基吉未治疗梅毒研究与公众对生物医学研究的认知：一项焦点小组研究
J Natl Med Assoc. 2004 Aug;96(8):1051-64.
10
The APO E4 allele and cognition in New Mexico Hispanic elderly.新墨西哥州西班牙裔老年人中的载脂蛋白E4等位基因与认知
Ethn Dis. 2002 Spring;12(2):235-41.
Zotero 插件